CLOs on the Move

Ottobock North America

www.ottobockus.com

 
Ottobock was founded in Germany in 1919 by Otto Bock, a prosthetist. His vision of restoring mobility lives on today, growing to serve the world with more than 46 locations reaching more than 100 countries. The company is headquartered in Duderstadt, Germany, and has more than 5,000 employees.   In the early 20th century, Otto Bock transformed the way prosthetic limbs were made. Instead of carving wood to fit a patient, he applied manufacturing techniques and created separate components (like knees and feet) that could be combined, altered or customized to create a limb that was still unique to each patient – ...
  • Number of Employees: 250-1000
  • Annual Revenue: $250-500 Million
  • www.ottobockus.com
  • Riata Corporate Park, Building 8 12365 - B Riata Trace Parkway, Suite 250
    Austin, TX USA 78727
  • Phone: 800.328.4058

Executives

Name Title Contact Details

Similar Companies

LL Tech Inc

LL Tech Inc is a Princeton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Epocrates

Epocrates, Inc. is a provider of clinical information and decision support tools to healthcare professionals, as well as interactive information services to the healthcare industry. As of April 17, 2008, the Company has subscriber base of over 500,000

Cardiomend Inc

Cardiomend Inc is a Santa Barbara, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

XRI Inc

XRI Inc is a Warwick, RI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

TriVascular

TriVascular has pioneered numerous design and manufacturing technologies in pursuit of our commitment to providing optimal solutions for endovascular aortic repair (EVAR). TriVascular`s initial product offerings are novel endovascular grafts focused on significantly advancing EVAR. Building upon partnerships with thought leading clinicians worldwide, TriVascular`s products are designed to address unmet clinical needs and expand the pool of patients who are candidates for EVAR.